Korean Journal of Clinical Pharmacy (한국임상약학회지)

Korean College Of Clinical Pharmacy (한국임상약학회)
권호 표지

Analysis of Ethnic Differences in Physician's Desk Reference

Physician's Desk Reference에 나타난 인종차이 분석

  • Kim, Eun Jung (Graduate School of Clinical Health Sciences, Ewha Womans University) ;
  • Lee, Kyung Eun (College of Pharmacy and Division of Life & Pharmaceutical Sciences, Ewha Womans University) ;
  • Gwak, Hye Sun (College of Pharmacy and Division of Life & Pharmaceutical Sciences, Ewha Womans University)
  • 김은정 (이화여자대학교 임상보건과학대학원) ;
  • 이경은 (이화여자대학교 약학대학/생명약학부) ;
  • 곽혜선 (이화여자대학교 약학대학/생명약학부)
  • Received : 2012.12.12
  • Accepted : 2013.05.08
  • Published : 2013.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: The aim of study was to investigate the racial or ethnic differences in FDA-approved medications. Methods: Data on racial-based differences of drugs in PDR (Physician's Desk Reference) were analyzed by searching with keywords, "ETHNIC" and "RACE". Results: There were descriptions related to "ETHNIC" in product directions of 53 cases and "RACE" in 266 cases in 2010 PDR. After excluding 30 cases of duplicates, 289 cases were shown of which 28 cases were verified to demonstrate racial or ethnic differences. Drug category showing the higher racial or ethnic differences was cardiovascular drugs (7), followed by alimentary tract and metabolism drugs (6), nervous system drugs (5), and antineoplastic and immunomodulating agents (3). Pharmacokinetic differences between race and ethnicity were observed most frequently; differences in AUC or Cmax showed in 15 drugs and clearance differences in 7 drugs. Conclusions: This study identified the racial differences in medication usage in PDR. Therefore, the results can contribute to safe use of medication in real clinical settings in regards to the racial or ethnic differences.

Keywords

References

  1. Yasuda SU, Zhang L, Huang SM, The role of ethnicity in Variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008; 84(3): 417-423. https://doi.org/10.1038/clpt.2008.141
  2. McDowell SE, Coleman. JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006; 332(7551): 1177-82. https://doi.org/10.1136/bmj.38803.528113.55
  3. Larisa H, Lam F. Pharmacogenetics. In: Dipitro JT, et al., eds Pharmacotherapy: a pathophysiologic approach. 5th ed. New York: Mc Graw Hill, 2002; 55-59.
  4. Miners JO, Birkett DJ. Cytochrome P450 2C9: an enzyme of major importance in human drug metabolism. Br J Clin Pharmacol 1998; 45(6): 525-38. https://doi.org/10.1046/j.1365-2125.1998.00721.x
  5. Scott SA, Khasawneh R, Peter I, et al., Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups. Pharmacogenomics 2010; 11(6): 781-91. https://doi.org/10.2217/pgs.10.49
  6. McDowell SE, Coleman. JJ, Ferner RE. Systematic review and meta-analysis of ethnic differences in risks of adverse reactions to drugs used in cardiovascular medicine. BMJ 2006; 332(7551): 1177-82. https://doi.org/10.1136/bmj.38803.528113.55
  7. 가교자료평가 가이드라인. 식품의약품안전청. 발간등록번호 11-1470000-001719-01
  8. Campbell D, Chui M, Pharmerging Shake-up: new imperatives in a re-defined world. Northwalk: IMS, 2010.
  9. PDR(R) Electronic Library on CD-ROM, 64 edition. Montvale, NJ: PDR Network, LLC, 2010.
  10. ICH, Ethnic Factors In The Acceptability of Foreign Clinical Data E5(R1), Feb. 1998.(http://www.ich.org/fileadmin/Public_ Web_Site/ICH_Products/Guidelines/Efficacy/E5_R1/Step4/ E5_R1__Guideline.pdf)
  11. FDA. Investigational new drug applications and new drug applications Final rule. Fed Regist 1998; 63(28): 6854-62.
  12. FDA. Guidance for industry Collection of Race and Ethnicity Data in Clinical Trials, Sep. 2005. (http://www. fda.gov/downloads/RegulatoryInformation/Guidances/ucm 126396.pdf)
  13. Department of Health and Human Service (http:// www.hhs.gov)
  14. Centers for Disease Control and Prevention (http:// www.cdc.gov)
  15. Prostate Cancer Screening: A Decision Guide for African Americans, CDC, 2003
  16. Rotimi CN, Jorde LB. Ancestry and disease in the age of genomic medicine. N Engl J Med. 2010; 363(16): 1551-8. https://doi.org/10.1056/NEJMra0911564
  17. Asian & Pacic Islander American Health Forum (http:// www.apiahf.org)
  18. The International Society on Hypertension in Blacks (http://www.ishib.org)
  19. Dugluas JG, Bakris GL, Epstein M, et al., Management of high blood pressure in african americans. Arch Intern Med 2003; 163(5): 525-41. https://doi.org/10.1001/archinte.163.5.525
  20. Flack JM, Sica DA, Bakris G, et al., Management of high blood pressure in blacks; an update of the international society on hypertension in blacks consensus statement. Hypertension 2010; 56: 780-800. https://doi.org/10.1161/HYPERTENSIONAHA.110.152892
  21. Séguin B, Hardy B, Singer PA, et al., $BiDil^{(R)}$: recontextualizing the race debate. Pharmacogenomics J 2008; 8(3): 169-73. https://doi.org/10.1038/sj.tpj.6500489